- Home
- ONFO vs CMND Comparison
ONFO vs CMND Comparison
Compare ONFO & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- CMND
- Stock Information
- Founded
- ONFO 2018
- CMND 2017
- Country
- ONFO United States
- CMND Canada
- Employees
- ONFO N/A
- CMND N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- CMND Health Care
- Exchange
- ONFO Nasdaq
- CMND Nasdaq
- Market Cap
- ONFO 5.8M
- CMND 5.2M
- IPO Year
- ONFO 2022
- CMND N/A
- Fundamental
- Price
- ONFO $1.04
- CMND $0.99
- Analyst Decision
- ONFO
- CMND
- Analyst Count
- ONFO 0
- CMND 0
- Target Price
- ONFO N/A
- CMND N/A
- AVG Volume (30 Days)
- ONFO 8.4K
- CMND 87.7K
- Earning Date
- ONFO 05-16-2025
- CMND 06-12-2025
- Dividend Yield
- ONFO N/A
- CMND N/A
- EPS Growth
- ONFO N/A
- CMND N/A
- EPS
- ONFO N/A
- CMND N/A
- Revenue
- ONFO $9,087,118.00
- CMND N/A
- Revenue This Year
- ONFO N/A
- CMND N/A
- Revenue Next Year
- ONFO N/A
- CMND N/A
- P/E Ratio
- ONFO N/A
- CMND N/A
- Revenue Growth
- ONFO 50.04
- CMND N/A
- 52 Week Low
- ONFO $0.49
- CMND $0.85
- 52 Week High
- ONFO $1.88
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- ONFO 45.70
- CMND 47.58
- Support Level
- ONFO $1.01
- CMND $0.94
- Resistance Level
- ONFO $1.10
- CMND $1.05
- Average True Range (ATR)
- ONFO 0.02
- CMND 0.06
- MACD
- ONFO -0.00
- CMND 0.00
- Stochastic Oscillator
- ONFO 40.00
- CMND 38.22
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.